Related Experiment Video

Updated: Jun 11, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

The mitogen-activated protein kinase kinase 4 has a pro-oncogenic role in skin cancer

Katherine G Finegan1, Cathy Tournier

  • 1Faculty of Life Sciences, University of Manchester, Michael Smith Building, Oxford Road, Manchester, United Kingdom.

Cancer Research
|July 9, 2010
PubMed

Insights

Mitogen-activated protein kinase kinase 4 (MKK4) plays a key role in Ras-driven skin cancer. Loss of MKK4 prevents tumor formation, highlighting its potential as a cancer drug target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Mitogen-activated protein kinase (MAPK) kinase 4 (MKK4) is involved in stress signaling pathways.
  • The role of MKK4 in tumorigenesis is controversial, with conflicting reports suggesting both tumor suppressive and oncogenic functions.

Purpose of the Study:

  • To investigate the specific role of MKK4 in epidermal tumorigenesis using a novel mouse model.
  • To clarify the function of MKK4 in the context of activated Ras mutations in skin cancer.

Main Methods:

  • Generation of a novel mouse model with skin-specific MKK4 deficiency.
  • Assessment of susceptibility to carcinogen-induced papilloma formation in MKK4-deficient mice.
  • Analysis of the underlying molecular mechanisms, including epidermal growth factor receptor (EGFR) and c-Jun signaling pathways.

Main Results:

  • Skin-specific MKK4-deficient mice exhibited resistance to carcinogen-induced skin tumorigenesis.
  • MKK4 was found to promote cell proliferation and tumor formation by upregulating epidermal growth factor receptor (EGFR) expression via the c-Jun NH(2)-terminal protein kinase (JNK)/c-Jun pathway.
  • This study provides the first genetic evidence for MKK4's essential role in mediating Ras oncogenic effects in vivo.

Conclusions:

  • MKK4 is essential for Ras-mediated skin tumorigenesis in vivo.
  • MKK4 acts by increasing EGFR expression through the JNK/c-Jun pathway.
  • MKK4 represents a potential therapeutic target for cancer treatment, particularly in Ras-driven cancers.

More Related Videos

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression11:02

The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression

Published on: August 3, 2011

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...